Q2 FY2026 · ended Jun 30, 2026 · Revenue $182,000, +51.7% YoY · Filed Aug 13, 2026
BioXcel Therapeutics, Inc. (BTAIQ) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $182,000 and a net loss of $14.7 million. Free cash flow was -$6.1 million. As of Jun 30, 2026 it held $12.8 million in cash and investments and $104.5 million in total debt.
Revenue
$182,000
+51.7% vs year-ago quarter
Net income
$-14.71M
+23.3% vs year-ago quarter
Operating cash flow
$-6.10M
+51.5% vs year-ago quarter
Free cash flow
$-6.10M
+51.5% vs year-ago quarter
EPS
$-0.49
+80.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
31.31M
+115.1% vs year-ago quarter
Net cash
$-91.61M
Q2 FY2026
Operating margin
-6054.7%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BTAIQ (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New Haven, CT
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1720893
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $182,000 | $206,000 | $256,000 | $98,000 | $120,000 |
| Operating income | -$10.2M | -$10.2M | -$10.3M | -$14.2M | -$15.9M |
| Net income | -$14.7M | -$12.7M | -$12.5M | -$30.9M | -$19.2M |
| Diluted EPS | -$0.49 | -$0.54 | -$0.58 | -$2.18 | -$2.45 |
| Operating cash flow | -$6.1M | -$11.8M | -$14.2M | -$18.8M | -$12.6M |
| Free cash flow | -$6.1M | -$11.8M | -$14.2M | -$18.8M | -$12.6M |
| Total assets | $28.8M | $34.0M | $44.9M | $44.8M | $25.8M |
| Total liabilities | $144.3M | $139.6M | $140.4M | $133.7M | $133.5M |
| Stockholders' equity | -$115.5M | -$105.5M | -$95.5M | -$88.9M | -$107.7M |
| Cash and investments | $12.8M | $17.2M | $28.4M | $36.2M | $17.4M |
| Total debt | $104.5M | $100.3M | $109.7M | $109.3M | $108.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Acquisition or sale of assets, Officer or director change, Bylaw or fiscal year change
|
Oct 30, 2026 | Oct 26, 2026 |
| 8-K |
Current report
New debt, Listing notice
|
Sep 1, 2026 | Aug 31, 2026 |
| 8-K |
Current report
Material agreement, Bankruptcy
|
Aug 28, 2026 | Aug 27, 2026 |
| 8-K |
Current report
Material agreement
|
Aug 25, 2026 | Aug 24, 2026 |
| 8-K |
Current report
Material agreement
|
Aug 24, 2026 | Aug 21, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
All 672 BioXcel Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.